1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. Wisconsin >
  6. MilliporeSigma Acquires Mirus Bio

M&A Deal Summary

MilliporeSigma Acquires Mirus Bio

On May 22, 2024, MilliporeSigma acquired life science company Mirus Bio from Gamma Biosciences for 600M USD

Acquisition Highlights
  • This is MilliporeSigma’s 1st transaction in the Life Science sector.
  • This is MilliporeSigma’s largest (disclosed) transaction.
  • This is MilliporeSigma’s 2nd transaction in the United States.
  • This is MilliporeSigma’s 1st transaction in Wisconsin.

M&A Deal Summary
Date 2024-05-22
Target Mirus Bio
Sector Life Science
Buyer(s) MilliporeSigma
Sellers(s) Gamma Biosciences
Deal Type Divestiture
Deal Value 600M USD

Target

Mirus Bio

Madison, Wisconsin, United States
Mirus Bio is a developer of biomimetic, cell-adaptive lipid-polymer nanocomplexes (LPNCs) for nucleic acid delivery. Mirus Bio's expertise in nucleic acid delivery gives life scientists the most advanced tools for gene expression, biotherapeutic protein production, virus manufacturing, and genome editing. Mirus Bio was founded in 1995 and is based in Madison, Wisconsin.

Search 205,401 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

MilliporeSigma

Burlington, Massachusetts, United States
Category Company
Sector Life Science
DESCRIPTION

MilliporeSigma is a provider of U.S. and Canada life science business of of Merck KGaA.

DEAL STATS #
Overall 2 of 3
Sector (Life Science) 1 of 2
Type (Divestiture) 2 of 2
State (Wisconsin) 1 of 1
Country (United States) 2 of 2
Year (2024) 1 of 2
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-04-05 MAST Platform

Bend, Oregon, United States

The MAST® platform enables the gathering of more frequent samples and collection of real-time data, including product attributes in hours instead of weeks, compared to manual sampling. The average cell culture process can save more than 80 hours of labor generally required for sample collection, handling, and analysis. The MAST® platform is based in Bend, Oregon.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-12-17 HUB

Utrecht, Netherlands

HUB offers patient-derived organoid technology that enables drug developers to identify and validate clinical candidates in a patient-relevant in vitro system. HUB Organoid Technology represents a paradigm shift for drug discovery and development, preclinical patient stratification, predictive diagnostics, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics. HUB offers licenses to its proprietary technology and provides drug development services using its living organoid biobanks. HUB is based in Utrecht, Netherlands.

Buy -

Seller(S) 1

SELLER

Gamma Biosciences

Menlo Park, California, United States
Category Company
Founded 2020
Sector Life Science
DESCRIPTION

Gamma Biosciences is a life sciences company providing products and services to support the development and manufacturing of advanced biologic therapies. Gamma Biosciences was founded in 2020 and is based in Menlo Park, California.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Wisconsin) 1 of 1
Country (United States) 1 of 1
Year (2024) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-09-23 Nirrin Technologies

Billerica, Massachusetts, United States

Nirrin Technologies is a provider of next-generation sensors and analytics for real-time, in-process monitoring and analysis in upstream and downstream bioprocessing applications for the biopharma and life science industries. Nirrin Technologies is based in Billerica, Massachusetts.

Buy -
Mergr

Product

Company

Legal